<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2023-2840</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2840</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POINT OF VIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОЧКА ЗРЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Myocardial electroporation — an alternative to thermal methods of atrial fibrillation treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Электропорация миокарда — альтернатива термическим методам лечения фибрилляции предсердий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2530-361X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арчаков</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Archakov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арчаков Евгений Александрович</p></bio><bio xml:lang="en"><p>Evgenii A. Archakov</p></bio><email xlink:type="simple">aea_cardio@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1415-3932</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баталов</surname><given-names>Р. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Batalov</surname><given-names>R. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баталов Роман Ефимович</p></bio><bio xml:lang="en"><p>Roman E. Batalov</p></bio><email xlink:type="simple">romancer@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9885-5204</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлынин</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlynin</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хлынин Михаил Сергеевич</p></bio><bio xml:lang="en"><p>Mikhail S. Khlynin</p></bio><email xlink:type="simple">mskhlynin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6531-7223</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сморгон</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smorgon</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сморгон Андрей Владимирович</p></bio><bio xml:lang="en"><p>Andrey V. Smorgon</p></bio><email xlink:type="simple">sav.ssmu@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9050-4493</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попов Сергей Валентинович</p></bio><bio xml:lang="en"><p>Sergey V. Popov</p></bio><email xlink:type="simple">psv@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский  медицинский центр РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>27</day><month>07</month><year>2023</year></pub-date><volume>19</volume><issue>3</issue><fpage>277</fpage><lpage>281</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Archakov E.A., Batalov R.E., Khlynin M.S., Smorgon A.V., Popov S.V., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Арчаков Е.А., Баталов Р.Е., Хлынин М.С., Сморгон А.В., Попов С.В.</copyright-holder><copyright-holder xml:lang="en">Archakov E.A., Batalov R.E., Khlynin M.S., Smorgon A.V., Popov S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2840">https://www.rpcardio.online/jour/article/view/2840</self-uri><abstract><p>Atrial fibrillation is one of the most common cardiac arrhythmias. By all estimates, the number of patients with this arrhythmia will only increase. Currently, the main and most used methods for the treatment of atrial fibrillation are radiofrequency and cryo-balloon ablation. However, the accumulated experience of their use has revealed a number of shortcomings — the lack of long-term pulmonary vein isolation, as well as life-threatening procedure complications. Relatively recent foreign studies showed data on the use of an alternative method of influencing arrhythmogenic foci. The method is based on the use of non-thermal pulsed field ablation, which leads to the appearance of pores in cardiomyocytes and their necrosis, which causes a more stable electrical left atrial pulmonary vein isolation. The margins of the lesions in this exposure are usually very sharp with a narrow transition from normal tissue to tissue with the complete necrosis, while not damaging neighboring structures such as blood vessels, nerves and esophagus. At present, information published in the literature on the use of pulsed field ablation in various fields of medicine, including oncology and cardiology, is clearly not enough. The implementation of this method for the interventional treatment of cardiac arrhythmias is considered a promising direction and is the subject of research by many leading scientific groups around the world. The purpose of this review is to structure the most significant information on the use of pulsed field ablation, presented in the literature, to analyze its possibilities, effectiveness, and disadvantages.</p></abstract><trans-abstract xml:lang="ru"><p>Фибрилляция предсердий — одна из самых распространенных аритмий сердца. По всем оценкам количество больных с этой аритмией будет только увеличиваться. В настоящее время основными и часто используемыми методами лечения фибрилляции предсердий являются радиочастотная и криобалонная аблации. Однако накопленный опыт их применения выявил ряд недостатков — отсутствие долгосрочной изоляции легочных вен, иногда возникающие осложнения процедуры, которые грозят серьезными последствиями вплоть до рисков летального исхода. Относительно недавно в зарубежной литературе появились сведения о применении альтернативного способа воздействия на аритмогенные очаги. Метод основан на применении нетермической аблации импульсным полем (АИП), которая приводит к появлению пор в кардиомиоцитах и их некрозу, что вызывает более устойчивую электрическую изоляцию легочных вен в левом предсердии. Края поражений при этом воздействии обычно очень четкие с узкой зоной перехода от нормальной ткани к ткани с полным некрозом, при этом без повреждения соседних структур, например, таких как кровеносные сосуды, нервы и пищевод. В настоящее время опубликованной в литературе информации по использованию АИП в различных областях медицины, в том числе онкологии и кардиологии, явно недостаточно. Реализация этого метода для интервенционного лечения сердечных аритмий считается перспективным направлением и является объектом исследования многих ведущих научных групп по всему миру. Цель данного обзора — структурировать наиболее значимые сведения о применении АИП, представленные в литературе, проанализировать ее возможности, эффективность и недостатки.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>радиочастотная аблация</kwd><kwd>криобалонная аблация</kwd><kwd>аблация импульсным полем</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>radiofrequency ablation</kwd><kwd>cryo-balloon ablation</kwd><kwd>pulsed field ablation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. DOI:10.1016/j.jacc.2020.11.010.</mixed-citation><mixed-citation xml:lang="en">Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. DOI:10.1016/j.jacc.2020.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Эшматов О.Р., Баталов Р. Е., Арчаков Е. А. и др. Эффективность и безопасность антикоагулянтной терапии у пациентов с различными формами фибрилляции предсердий после интервенционного лечения. Результаты трехлетнего наблюдения. Кардиология. 2022;62(8):19-26]. DOI:10.18087/cardio.2022.8.n2046.</mixed-citation><mixed-citation xml:lang="en">Eshmatov OR, Batalov RE, Archakov EA, et al. Efficacy and safety of anticoagulant therapy in patients with various forms of atrial fibrillation after interventional treatment. The results of a three-year follow-up. Kardiologiia. 2022;62(8):19-26 (In Russ.) DOI:10.18087/cardio.2022.8.n2046.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chavez P, Messerli FH, Casso Dominguez A, et al. Atrioesophageal fistula following ablation procedures for atrial fibrillation: systematic review of case reports. Open Heart. 2015;2(1):e000257. DOI:10.1136/openhrt-2015-000257.</mixed-citation><mixed-citation xml:lang="en">Chavez P, Messerli FH, Casso Dominguez A, et al. Atrioesophageal fistula following ablation procedures for atrial fibrillation: systematic review of case reports. Open Heart. 2015;2(1):e000257. DOI:10.1136/openhrt-2015-000257.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Krassowska W. Effects of electroporation on transmembrane potential induced by defibrillation shocks. Pacing Clin Electrophysiol. 1995;18(9 Pt 1):1644-1660. DOI:10.1111/j.1540-8159.1995.tb06986.x.</mixed-citation><mixed-citation xml:lang="en">Krassowska W. Effects of electroporation on transmembrane potential induced by defibrillation shocks. Pacing Clin Electrophysiol. 1995;18(9 Pt 1):1644-1660. DOI:10.1111/j.1540-8159.1995.tb06986.x.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">du Pré BC, van Driel VJ, van Wessel H, et al. Minimal coronary artery damage by myocardial electroporation ablation. Europace. 2013;15(1):144-149. DOI:10.1093/europace/eus171.</mixed-citation><mixed-citation xml:lang="en">du Pré BC, van Driel VJ, van Wessel H, et al. Minimal coronary artery damage by myocardial electroporation ablation. Europace. 2013;15(1):144-149. DOI:10.1093/europace/eus171.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zager Y, Kain D, Landa N, et al. Optimization of Irreversible Electroporation Protocols for In-vivo Myocardial Decellularization. PLoS One. 2016;11(11): e0165475. DOI:10.1371/journal.pone.0165475.</mixed-citation><mixed-citation xml:lang="en">Zager Y, Kain D, Landa N, et al. Optimization of Irreversible Electroporation Protocols for In-vivo Myocardial Decellularization. PLoS One. 2016;11(11): e0165475. DOI:10.1371/journal.pone.0165475.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sugrue A, Vaidya VR, Livia C, et al. Feasibility of selective cardiac ventricular electroporation. PLoS One. 2020;15(2):e0229214. DOI:10.1371/journal.pone.0229214.</mixed-citation><mixed-citation xml:lang="en">Sugrue A, Vaidya VR, Livia C, et al. Feasibility of selective cardiac ventricular electroporation. PLoS One. 2020;15(2):e0229214. DOI:10.1371/journal.pone.0229214.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kotnik T, Frey W, Sack M, et al. Electroporation-based applications in bio technology. Trends Biotechnol. 2015;33(8):480-488. DOI:10.1016/j.tibtech.2015.06.002.</mixed-citation><mixed-citation xml:lang="en">Kotnik T, Frey W, Sack M, et al. Electroporation-based applications in bio technology. Trends Biotechnol. 2015;33(8):480-488. DOI:10.1016/j.tibtech.2015.06.002.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tekle E, Astumian RD, Chock PB. Electroporation by using bipolar oscillating electric field: an improved method for DNA transfection of NIH 3T3 cells. Proc Natl Acad Sci USA. 1991;88(10):4230-4234. DOI:10.1073/pnas.88.10.4230.</mixed-citation><mixed-citation xml:lang="en">Tekle E, Astumian RD, Chock PB. Electroporation by using bipolar oscillating electric field: an improved method for DNA transfection of NIH 3T3 cells. Proc Natl Acad Sci USA. 1991;88(10):4230-4234. DOI:10.1073/pnas.88.10.4230.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chang DC. Cell poration and cell fusion using an oscillating electric field. Biophys J. 1989;56(4):641-652. DOI:10.1016/S0006-3495(89)82711-0.</mixed-citation><mixed-citation xml:lang="en">Chang DC. Cell poration and cell fusion using an oscillating electric field. Biophys J. 1989;56(4):641-652. DOI:10.1016/S0006-3495(89)82711-0.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Neven K, van Driel V, van Wessel H, et al. Epicardial linear electroporation ablation and lesion size. Heart Rhythm. 2014;11(8):1465-1470. DOI:10.1016/j.hrthm.2014.04.031.</mixed-citation><mixed-citation xml:lang="en">Neven K, van Driel V, van Wessel H, et al. Epicardial linear electroporation ablation and lesion size. Heart Rhythm. 2014;11(8):1465-1470. DOI:10.1016/j.hrthm.2014.04.031.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Neven K, van Driel V, van Wessel H, et al. Safety and feasibility of closed chest epicardial catheter ablation using electroporation. Circ Arrhythm Electro - physiol. 2014;7(5):913-919. DOI:10.1161/CIRCEP.114.001607.</mixed-citation><mixed-citation xml:lang="en">Neven K, van Driel V, van Wessel H, et al. Safety and feasibility of closed chest epicardial catheter ablation using electroporation. Circ Arrhythm Electro - physiol. 2014;7(5):913-919. DOI:10.1161/CIRCEP.114.001607.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Padmanabhan D, Naksuk N, Killu AK, et al. Electroporation of epicardial autonomic ganglia: Safety and efficacy in medium-term canine models. J Cardiovasc Electrophysiol. 2019;30(4):607-615. DOI:10.1111/jce.13860.</mixed-citation><mixed-citation xml:lang="en">Padmanabhan D, Naksuk N, Killu AK, et al. Electroporation of epicardial autonomic ganglia: Safety and efficacy in medium-term canine models. J Cardiovasc Electrophysiol. 2019;30(4):607-615. DOI:10.1111/jce.13860.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295-300. DOI:10.1177/153303460700600405.</mixed-citation><mixed-citation xml:lang="en">Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295-300. DOI:10.1177/153303460700600405.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lyu T, Wang X, Su Z, et al. Irreversible electroporation in primary and metastatic hepatic malignancies: A review. Medicine (Baltimore). 2017;96(17):e6386. DOI:10.1097/MD.0000000000006386.</mixed-citation><mixed-citation xml:lang="en">Lyu T, Wang X, Su Z, et al. Irreversible electroporation in primary and metastatic hepatic malignancies: A review. Medicine (Baltimore). 2017;96(17):e6386. DOI:10.1097/MD.0000000000006386.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lavee J, Onik G, Mikus P, et al. A novel nonthermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg Forum. 2007;10(2):E162-E167. DOI:10.1532/HSF98.20061202.</mixed-citation><mixed-citation xml:lang="en">Lavee J, Onik G, Mikus P, et al. A novel nonthermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg Forum. 2007;10(2):E162-E167. DOI:10.1532/HSF98.20061202.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sugrue A, Vaidya V, Witt C, et al. Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience. J Interv Card Electrophysiol. 2019;55(3):251-265. DOI:10.1007/s10840-019-00574-3.</mixed-citation><mixed-citation xml:lang="en">Sugrue A, Vaidya V, Witt C, et al. Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience. J Interv Card Electrophysiol. 2019;55(3):251-265. DOI:10.1007/s10840-019-00574-3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hunter DW, Kostecki G, Fish JM, et al. In Vitro Cell Selectivity of Reversible and Irreversible: Electroporation in Cardiac Tissue. Circ Arrhythm Electrophysiol. 2021;14(4):e008817. DOI:10.1161/CIRCEP.120.008817.</mixed-citation><mixed-citation xml:lang="en">Hunter DW, Kostecki G, Fish JM, et al. In Vitro Cell Selectivity of Reversible and Irreversible: Electroporation in Cardiac Tissue. Circ Arrhythm Electrophysiol. 2021;14(4):e008817. DOI:10.1161/CIRCEP.120.008817.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ye X, Liu S, Yin H, et al. Study on Optimal Parameter and Target for PulsedField Ablation of Atrial Fibrillation. Front Cardiovasc Med. 2021;8:690092. DOI:10.3389/fcvm.2021.690092.</mixed-citation><mixed-citation xml:lang="en">Ye X, Liu S, Yin H, et al. Study on Optimal Parameter and Target for PulsedField Ablation of Atrial Fibrillation. Front Cardiovasc Med. 2021;8:690092. DOI:10.3389/fcvm.2021.690092.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Koruth J, Kuroki K, Iwasawa J, et al. Preclinical Evaluation of Pulsed Field Ablation: Electrophysiological and Histological Assessment of Thoracic Vein Isolation. Circ Arrhythm Electrophysiol. 2019;12(12):e007781. DOI:10.1161/CIRCEP.119.007781.</mixed-citation><mixed-citation xml:lang="en">Koruth J, Kuroki K, Iwasawa J, et al. Preclinical Evaluation of Pulsed Field Ablation: Electrophysiological and Histological Assessment of Thoracic Vein Isolation. Circ Arrhythm Electrophysiol. 2019;12(12):e007781. DOI:10.1161/CIRCEP.119.007781.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy VY, Koruth J, Jais P, et al. Ablation of Atrial Fibrillation With Pulsed Electric Fields: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation. JACC Clin Electrophysiol. 2018;4(8):987-995. DOI:10.1016/j.jacep.2018.04.005.</mixed-citation><mixed-citation xml:lang="en">Reddy VY, Koruth J, Jais P, et al. Ablation of Atrial Fibrillation With Pulsed Electric Fields: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation. JACC Clin Electrophysiol. 2018;4(8):987-995. DOI:10.1016/j.jacep.2018.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart MT, Haines DE, Verma A. et al. Intracardiac pulsed field ablation: Proof of feasibility in a chronic porcine model. Heart Rhythm. 2019;16(5):754-764. DOI:10.1016/j.hrthm.2018.10.030.</mixed-citation><mixed-citation xml:lang="en">Stewart MT, Haines DE, Verma A. et al. Intracardiac pulsed field ablation: Proof of feasibility in a chronic porcine model. Heart Rhythm. 2019;16(5):754-764. DOI:10.1016/j.hrthm.2018.10.030.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614-627. DOI:10.1016/j.jacep.2021.02.014.</mixed-citation><mixed-citation xml:lang="en">Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614-627. DOI:10.1016/j.jacep.2021.02.014.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ekanem E, Reddy VY, Schmidt B, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24(8):1256-1266. DOI:10.1093/europace/euac050.</mixed-citation><mixed-citation xml:lang="en">Ekanem E, Reddy VY, Schmidt B, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24(8):1256-1266. DOI:10.1093/europace/euac050.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
